841302-24-7

Basic information

• Product Name: Hydroxy Saxagliptin
• Synonyms: Hydroxy Saxagliptin;(1S,3S,5S)-2-[(2S)-2-aMino-2-(3,5-dihydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-2-Azabicyclo[3.1.0]hexane-3-carbonitrile;BMS 510849;5-Hydroxy Saxagliptin;2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-2-aMino-2- (3,5-dihydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-;(1S,3R,5S)-2-[(2S)-2-amino-2-[(3R,5S)-3,5-dihydroxy-1-adamantyl]acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;Saxagliptin Impurity 24;5-Hydroxy Saxagliptin Hydrochloride Labeled 15N,d2
• CAS NO: 841302-24-7
• Molecular Formula: C18H25N3O3
• Molecular Weight: 331.4094
• Product Categories: Amines;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 841302-24-7.mol

Chemical Properties

• Boiling Point: 589.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.43±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly), DCM
• PKA: 14.39±0.60(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: Hydroxy Saxagliptin(CAS DataBase Reference)
• NIST Chemistry Reference: Hydroxy Saxagliptin(841302-24-7)
• EPA Substance Registry System: Hydroxy Saxagliptin(841302-24-7)

Safety Data

• Hazardous Substances Data: 841302-24-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Hydroxy Saxagliptin is used as a metabolite of Saxagliptin for the treatment of type 2 diabetes. It plays a role in the body's metabolism of Saxagliptin, contributing to the overall effectiveness of the medication in managing blood sugar levels.

Upstream product

• 1564265-93-5 saxagliptin 

Relevant articles and documents

EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS

Methods and compositions for the catalytic oxidation of pharmaceutically active compounds, and more particularly to ex vivo methods for predicting in vivo metabolism of pharmaceutically active compounds, including predicting in vivo interaction between two or more pharmaceutically active compounds.

ADAMANTYGLYCINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS

Compounds are provided having the formula (I) [Chemical Structure] wherein: n is 0, 1 or 2; m is 0, 1 or 2; the sum of n + m less then or equal to 2; the dashed bonds forming a cyclopropyl ring can only be present when Y is CH; X is H or CN; Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.